Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
E. Gabriela Chiorean, MD, highlights the importance of consistently testing for biomarkers with RNA-based tests in addition to DNA-based. She also details key biomarkers and the upcoming 9th Annual School of Gastrointestinal Oncology® conference.
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Golden, Colorado, Nov. 03, 2023 Theralink Technologies, Inc. , a precision oncology company with its exclusive commercial RPPA technology that can help predict which FDA-approved drug is.